Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New balloon could keep leg arteries open longer

NCT ID NCT05734157

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a special balloon coated with the drug everolimus to treat blockages in the leg's main arteries. The balloon is inflated inside the artery to push the blockage open and release the drug to help prevent the artery from narrowing again. The trial included 75 people with blocked or narrowed femoral or popliteal arteries. The goal was to see if the balloon is safe and effective at keeping the artery open and reducing the need for repeat treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
everolimus-coated balloon
What this could lead to
If successful, this could provide a better way to treat blocked leg arteries, reducing the chance of repeat blockages and the need for further procedures.
What could go wrong
This is a first-in-human study with only 75 participants, so results may not apply to everyone. The balloon may not keep arteries open as hoped, and there are risks like vessel damage or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

75 people

The number who actually took part.

Started

Feb 2022

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject must be at least 18 years of age. 2. Subject or his/her legally authorized representative provides written informed consent prior to any clinical investigation related procedure, as approved by the appropriate Ethics Committee of the respective clinical site. 3. Subject must agree to undergo all clinical investigation plan-required follow-up visits and examinations. 4. Subjects with symptomatic leg ischemia, requiring treatment of SFA or popliteal (P1 segment) artery. 5. De novo or restenotic lesion(s) \>70% within the SFA and popliteal arteries in a single limb which are ≥3 cm and ≤15 cm in cumulative total length (by visual estimation). Lesion must be at least 2 cm from any stented area. 6. Subject is willing to comply with the required follow up visits, testing schedule and medication regimen. 7. Successful wire crossing of lesion. 8. Target vessel reference diameter ≥4 mm and ≤6 mm (by visual estimation). 9. Target lesion(s) can be treated with a maximum of two (2) CVT Everolimus-coated PTA Catheters. 10. At least one patent (less than 50% stenosis) tibio-peroneal run-off vessel confirmed by baseline angiography or prior MR angiography or CT angiography. 11. Life expectancy \>1 year 12. Rutherford classification of 2, 3 or 4. Exclusion Criteria: 1. Pregnant or lactating females. 2. Co-existing clinically significant aneurismal disease of the abdominal aorta, iliac or popliteal arteries. 3. Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy. 4. Known intolerance to study medications, everolimus or contrast agents. 5. Doubts in the willingness or capability of the subject to allow follow-up examinations. 6. Subject is actively participating in another investigational device or drug study. 7. History of hemorrhagic stroke within 3 months of procedure. 8. Previous or planned surgical or interventional procedure within 30 days of index procedure. 9. Prior vascular surgery of the target lesion. 10. Lesion length is \<3 cm or \>15 cm or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured. 11. Known inadequate distal outflow. 12. Significant inflow disease. 13. Acute or sub-acute thrombus in target vessel. 14. Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloons, brachytherapy, lithotripsy). 15. Outflow arteries (distal popliteal, anterior or posterior tibial or peroneal arteries) with significant lesions (≥ 50% stenosis) may not be treated during the same procedure. 16. Treatment of the contralateral limb during the same procedure or within 30 days of the study procedure. 17. Rutherford classification of 0, 1, 5 or 6 18. Presence of prohibitive calcification that precludes adequate PTA treatment. 19. Subjects held in custody in an institution by official or court order.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Femoral artery occlusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinique Pasteur

    Toulouse, 31300, France

  • DIAKO Krankenhaus Flensburg

    Flensburg, 24939, Germany

  • Hôpital Nord Laennec - CHU de Nantes

    Saint-Herblain, 44800, France

  • Hôpital Paris Saint Joseph

    Paris, 75014, France

  • Institut für Radiologie, Kinderradiologie und interventionelle Therapie

    Berlin, 12351, Germany

  • Jüdisches Krankenhaus Berlin

    Berlin, 13347, Germany

  • Polyclinique Les Fleurs

    Ollioules, 83190, France

  • Romed Klinikum Rosenheim

    Rosenheim, 83022, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.